Medigus requests to begin final clinical trial
The company’s device treats GERD without the need for surgery or laparoscopy.
Medigus earlier said that it hoped to begin marketing of the SRS System in the US in early 2008. The system is designed to replace surgical procedures for treating severe GERD, which involve stitching a part of the stomach lining around the lower part of the esophagus in order to create pressure to prevent the reflux of stomach acid. This procedure either requires opening the abdomen or laparoscopy.
The SRS System uses instead a guided camera endoscope inserted down the esophagus into the upper part of the stomach, where it fastens the stomach lining around the esophagus at the touch of a button, without the need for cutting or anesthesia.
Yesterday, Medigus received the results of the preliminary trial of the SRS System on ten patients, which demonstrated that the device was safe for use and that the results were similar to the results achieved through surgical procedures. The company filed for the multi-center clinical trial on the basis of the results of the preliminary trial.
Published by Globes [online], Israel business news - www.globes.co.il - on August 2, 2007
© Copyright of Globes Publisher Itonut (1983) Ltd. 2007
- Tel Aviv market report
- Tel Aviv Stock Exchange
- Israeli stocks in NY
- Arbitrage gaps for dual-listed stocks
- Israeli stocks in Europe
- Israeli stocks on other markets
- Tel Aviv 25 options
- Mutual funds
- Current representative shekel rates
- Historical representative shekel rates
- Bank shekel rates
- Shekel/dollar options